Early Diagnosis and Treatment of Progressive Pulmonary Fibrosis

Joshua J. Solomon, MD


July 05, 2022

Interstitial lung disease (ILD) refers to a large and heterogeneous group of more than 200 parenchymal disorders. ILDs have many causes, including connective tissue diseases, environmental factors, and some medications. Between 10% and 60% of those with fibrosing ILD will develop a progressive phenotype.

In this ReCAP, Dr Joshua Solomon from National Jewish Health in Denver, Colorado, discusses advances in the understanding of ILDs, specifically in the evolving phenotype of progressive pulmonary fibrosis (PPF), which falls outside of the well-defined definitions of idiopathic pulmonary fibrosis.

Dr Solomon underscores the need for early identification of potential progressive lung diseases so that patients may be treated for underlying causes. He also reports on the multimodality treatment approach, which includes medication, comorbidity management, and pulmonary rehabilitation. In addition, he emphasizes the need for immediate referral to specialty care for patients with suspected PPF.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.